Welcome to our dedicated page for 908 Devices news (Ticker: MASS), a resource for investors and traders seeking the latest updates and insights on 908 Devices stock.
908 Devices Inc. (MASS) delivers innovative mass spectrometry solutions enabling real-time chemical analysis across safety, life sciences, and industrial sectors. This news hub provides investors and professionals with essential updates on corporate developments and technological advancements.
Access timely press releases, earnings reports, and strategic announcements in one centralized location. Our curated collection includes regulatory filings, product launch details, and partnership updates critical for understanding the company's market position.
Key updates cover:
- Financial performance and investor communications
- Breakthroughs in handheld/desktop analysis devices
- Industry-specific applications in biotech and forensics
- Global expansion initiatives and regulatory milestones
Bookmark this page for streamlined access to MASS's evolving story. Combine our news archive with SEC filings and market analysis tools for comprehensive due diligence.
908 Devices Inc. (NASDAQ: MASS) launched a new Oligos assay kit at the ASMS conference, designed for its ZipChip device, enabling rapid and accurate oligonucleotide analysis. The kit offers several advantages over traditional liquid chromatography, including:
- No harsh ion-pairing reagents
- Faster analysis
- High-resolution, accurate mass identification
This advancement supports biopharmaceutical labs and enhances 908 Devices' position in the growing market for therapeutic oligonucleotides.
908 Devices Inc. (NASDAQ: MASS) is set to showcase its advancements in mass spectrometry at the ASMS conference from October 31 to November 4 in Philadelphia. The company will highlight novel high-pressure mass spectrometry and microfluidics technologies aimed at accelerating drug discovery in metabolomics and proteomics. Notably, a new ZipChip assay kit will be introduced for rapid oligonucleotide analysis. Presentations will focus on improving analysis time and efficiency in various applications, demonstrating the company's significant role in evolving laboratory mass spectrometry.
908 Devices (NASDAQ: MASS) will report its Q3 2021 financial results before market open on
908 Devices (Nasdaq: MASS) reported Q2 2021 revenue of $8.3 million, marking a 49% increase from Q1 2021 but a 26% decline year-over-year due to a one-time shipment in Q2 2020. Desktop sales surged 70% compared to last year, contributing a third of total revenue. The company anticipates full-year revenue growth of 49% to 60%, adjusting guidance upward to $40-$43 million. Gross profit decreased to $4.4 million with a margin of 53%. Operating expenses rose to $11.8 million, resulting in a net loss of $7.4 million, or $0.27 per share. Cash reserves stand at $141 million.
908 Devices (NASDAQ: MASS) has announced the appointment of six new members to its Scientific Advisory Board (SAB), enhancing its expertise in proteomics. The new members, including renowned scientists like Prof. Ileana Cristea and Prof. John Yates, bring extensive knowledge in areas such as viral infection and mass spectrometry. Company leaders expect these additions will strengthen the development of their mass spectrometry and microfluidic technologies. This expansion follows the recent advancements in their platform capabilities for analyzing complex biological samples.
908 Devices (NASDAQ:MASS) has announced the expansion of its global channel distribution network, now spanning over 40 countries across six continents. CEO Kevin J. Knopp emphasized the company's commitment to supporting sales and customer demands as part of their 2021 growth strategy. Recent partnerships include Sartorius Korea Biotech, Rhenium Ltd. in Israel, and others across South America and Europe. To bolster this initiative, additional sales and support staff have been hired in key regions. This strategic growth aims to enhance the company's presence in critical markets for its handheld and desktop mass spectrometry devices.
908 Devices (NASDAQ:MASS) announced a successful collaboration with Transcenta, enhancing biopharmaceutical workflows in Hangzhou, China. Their ZipChip® device accelerated the measurement of monoclonal antibodies (mAbs), achieving results in under 10 minutes—100 times faster than traditional methods. Transcenta also adopted the REBEL® device for near real-time amino acid analysis, supporting continuous cell culture. This partnership highlights the efficacy of 908 Devices' tools in bioprocess improvements and emphasizes their growing presence in the Asia Pacific region.
908 Devices Inc. (Nasdaq: MASS) announced it will release its financial results for Q2 2021 on August 4, 2021, before market open. A conference call will follow at 5:30 a.m. PT / 8:30 a.m. ET, available via live webcast on the company’s website. The session will be archived for replay within 24 hours. 908 Devices specializes in mass spectrometry devices that serve critical applications in life sciences and forensics, showcasing its commitment to making laboratory tools more accessible.
908 Devices (NASDAQ:MASS) has announced partnerships with Sartorius and Securecell to enhance its REBEL™ platform for bioprocess labs. These integrations allow users to harness advanced data analytics and improve operational excellence in process development. Key features include seamless data flow from REBEL into Sartorius’ SIMCA for better data visualization and trend analysis, as well as enhanced monitoring capabilities with Securecell’s Lucullus for Critical Process Parameters. This collaboration aims to empower customers with actionable bioanalytics information and drive high yields in bioprocessing.
908 Devices (NASDAQ: MASS) has appointed Dr. Marcia Eisenberg, the chief scientific officer of Labcorp Diagnostics, to its Board of Directors. Dr. Eisenberg brings over 30 years of experience in biotechnology, molecular genetics, and forensic DNA testing, having developed many clinical assays. Kevin Hrusovsky, chairman of 908 Devices, lauded her proven track record and relevant expertise as a vital asset. This appointment follows the recent addition of two board members earlier this year, indicating ongoing efforts to strengthen its leadership team.